Waters Corporation (WAT)

Nov 5, 2026

Thermo Fisher Scientific has launched its first Orbitrap mass spectrometers dedicated to isotope ratio analysis: the Orbitrap Isora MS and Orbitrap Isora Pro MS. These instruments, integrated with the Vanquish Duo UHPLC System and new Isotope Discoverer Software, create a workflow that makes molecular-level isotope ratio analysis more accessible to researchers. This innovation aims to accelerate discoveries in environmental science, geoscience, bioscience, and food authenticity by providing detailed insights into compound origins and molecular processes.

Nov 4, 2026

Waters Corporation has acquired MOBILion Systems and its ion mobility technology to enter the $2 billion LC-MS proteomics market. While Waters' core business saw 9% growth driven by routine drug and environmental testing, the MOBILion acquisition represents a strategic research bet on proteomics, aiming to enhance throughput for large cohort studies through SLIM technology. The company projects increased organic growth and anticipates AI-related demand to potentially accelerate MOBILion's contribution to revenue.

Nov 3, 2026

Waters Corporation (NYSE: WAT) stock rose after reporting better-than-expected third-quarter results, raising its full-year outlook, and announcing the acquisition of MOBILion Systems Inc. The company's growth was driven by strong demand for laboratory instruments and consumables, especially fueled by GLP-1 drug testing and a recovery in its China Biosciences business. CEO Udit Batra highlighted that AI is already increasing demand for Waters' instruments as drugmakers accelerate research and development.

Nov 3, 2026

Waters (NYSE:WAT) reported robust third-quarter 2026 results, with revenue reaching $1.767 billion, surpassing guidance and achieving 9% organic growth. Adjusted earnings per share climbed 21% to $4.10, outperforming analyst estimates. The company also raised its full-year 2026 revenue and adjusted earnings guidance and completed the acquisition of MOBILion Systems to enhance its protein-analysis technology.

Nov 3, 2026

Waters Corporation reported robust Q3 2026 results with $1.767 billion in revenue, 9% organic growth, and 21% adjusted EPS growth, driven by strong performance in Analytical Sciences and a significant rebound in Biosciences China. The company raised its full-year 2026 revenue guidance by $43 million and provided an optimistic 2027 outlook, emphasizing strategic initiatives like AI integration, new product launches, and the MOBILion Systems acquisition to achieve high single-digit growth potential. Waters also highlighted its unique position in pharma QC with AI-powered Empower features and growing demand from AI-native biotech companies.

Nov 3, 2026

Waters Corp. (WAT) reported strong third-quarter results, with adjusted earnings of $4.10 per share and revenue of $1.77 billion, both exceeding Wall Street expectations. The company also provided an optimistic outlook for the current quarter and the full fiscal year, projecting higher earnings and revenue. These figures were generated by Automated Insights using data from Zacks Investment Research.

Nov 3, 2026

Waters Corp. (WAT) reported third-quarter earnings of $81 million, or 82 cents per share, which adjusted to $4.10 per share, surpassing Wall Street expectations. The company also exceeded revenue forecasts with $1.77 billion. Looking ahead, Waters projects fourth-quarter earnings between $4.58 and $4.68 per share and revenue from $1.8 billion to $1.9 billion, with full-year earnings expected between $14.60 and $14.70 per share and revenue between $6.48 billion and $6.5 billion.

Nov 3, 2026

Waters Corporation (NYSE:WAT) reported strong Q3 2026 results, with revenue up 121% year-on-year to $1.77 billion, surpassing Wall Street's expectations. The company also provided better-than-expected revenue guidance for Q4 2026 and slightly raised its full-year adjusted EPS guidance. Despite these positive indicators, shares edged lower immediately after the release, suggesting investors may have anticipated even stronger outcomes.

Nov 2, 2026

Waters Corp. (WAT) shares fell 2.85% on Monday, closing at $449.53, while the broader market experienced mixed trading with the Dow Jones Industrial Average rising and the S&P 500 Index declining. This marks the second consecutive day of losses for the stock.

Oct 29, 2026

Veralto (NYSE: VLTO) announced strong third-quarter 2026 results, with sales increasing 7.5% year-over-year to $1,509 million and adjusted earnings per share rising by 19.2%. The company reported significant strategic capital allocation, including $1.1 billion for four acquisitions and $550 million in share repurchases. Veralto also raised its full-year 2026 adjusted earnings per share guidance to $4.49 to $4.52, reflecting continued healthy demand across its Water Quality and Product Quality & Innovation segments.

Oct 29, 2026

Waters (NYSE: WAT) has outperformed the market over the last two decades, achieving an average annual return of 11.87% and outperforming the market by 2.93% on an annualized basis. An initial investment of $1000 in WAT stock 20 years ago would now be worth $9,591.72, highlighting the significant impact of compounded returns on cash growth over time.

Oct 28, 2026

Labcorp (LH) reported strong Q3 2026 results with a 6.9% increase in total revenue and 14.5% adjusted EPS growth, driven by organic volume and strategic acquisitions in both diagnostics and biopharma laboratory services. The company raised its 2026 guidance, reaffirming its long-term outlook despite anticipated reimbursement pressures from proposed PAMA changes. Labcorp also announced three strategic acquisitions and expanded its leadership in specialty testing, particularly in oncology and neurology.

Oct 28, 2026

Shares of Waters Corp. (WAT) saw a 1.78% increase, closing at $476.88 on Wednesday, outperforming the broader market. This marked the stock's third consecutive day of gains, aligning with a positive trading session for the S&P 500 Index and the Dow Jones Industrial Average.